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Single-cell imaging of CAR T cell activity in vivo
reveals extensive functional and anatomical
heterogeneity
Marine Cazaux1,2*, Capucine L. Grandjean1*, Fabrice Lemaˆıtre1, Zacarias Garcia1, Richard J. Beck3, Idan Milo1, Je´re´my Postat1,2, Joost B. Beltman3,
Eleanor J. Cheadle4, and Philippe Bousso1
CAR T cells represent a potentially curative strategy for B cell malignancies. However, the outcome and dynamics of CAR T cell
interactions in distinct anatomical sites are poorly understood. Using intravital imaging, we tracked interactions established by
anti-CD19 CAR T cells in B cell lymphoma–bearing mice. Circulating targets trapped CAR T cells in the lungs, reducing their
access to lymphoid organs. In the bone marrow, tumor apoptosis was largely due to CAR T cells that engaged, killed, and
detached from their targets within 25 min. Notably, not all CAR T cell contacts elicited calcium signaling or killing while
interacting with tumors, uncovering extensive functional heterogeneity. Mathematical modeling revealed that direct killing
was sufﬁcient for tumor regression. Finally, antigen-loss variants emerged in the bone marrow, but not in lymph nodes, where
CAR T cell cytotoxic activity was reduced. Our results identify a previously unappreciated level of diversity in the outcomes of
CAR T cell interactions in vivo, with important clinical implications.
Introduction
Chimeric antigen receptor (CAR) T cells represent a potentially
curative strategy for B cell malignancies. In recent clinical trials,
CAR T cells targeting the CD19 molecule have demonstrated
remarkable activity in the treatment of B cell leukemias and
B cell lymphomas (Maude et al., 2014; Neelapu et al., 2017;
Schuster et al., 2017; Park et al., 2018). Despite these promising
results, the cellular interactions regulating anti-CD19 CAR T cell
activity and tumor regression in vivo are incompletely under-
stood. First, CAR T cells may interact with target cells in various
anatomical sites and these contacts may potentially modulate
their activity and persistence. In this respect, CAR T cell num-
bers are inﬂuenced by endogenous B cells (Cheadle et al., 2010),
which can favor their accumulation in the lung (James et al.,
2009), although the underlying mechanism remains to be
characterized. Second, cellular interactions leading to tumor
regression are not fully understood. CAR T cell killing dynamics
have been analyzed in vitro (Davenport et al., 2015, 2018; Liadi
et al., 2015), but not in vivo, limiting our understanding of the
quantitative and qualitative requirements for CAR T cell–
mediated tumor regression. Another key unanswered question
is whether tumor regression is primarily the result of direct CAR
T cell killing or whether CAR T cells largely act by activating
other host immune cells at the tumor site (Barber et al., 2009;
Chmielewski et al., 2011; Yeku et al., 2017). Finally, CAR T cell
therapy has been shown to favor the emergence of CD19-
negative tumors in some patients (Grupp et al., 2013; Maude
et al., 2014; Sotillo et al., 2015; Gardner et al., 2016; Jacoby
et al., 2016; Ruella and Maus, 2016), but the anatomical sites of
tumor escape have yet to be characterized.
To address these important questions, we visualized CAR
T cell activity in a mouse model of B cell aggressive lymphoma
using intravital imaging and a genetically encoded reporter for
apoptosis. CAR T cells that interacted with circulating targets
were trapped in the lungs in the form of large cell aggregates. At
the tumor site, CAR T cells exhibited extensive functional het-
erogeneity but harbored the potential to rapidly kill their tar-
gets, directly accounting for tumor regression. Finally, we
uncovered anatomical differences in tumor immunoediting as-
sociated with distinct levels of cytotoxic activity. Thus, the
outcomes of CAR T cell interactions in vivo are highly diverse
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and inﬂuenced both by functional properties and anatomical
speciﬁcities.
Results and discussion
Detecting CAR T cell–mediated killing using a genetically
encoded apoptosis reporter
To establish a mouse model of CAR T cell therapy, we used a
tumor cell line derived from a Eμ-myc transgenic mouse that
develops spontaneous Burkitt-like B cell lymphoma (Adams
et al., 1985; Harris et al., 1988). These cells expressed the CD19
marker, and when injected into recipient mice, established in
the bone marrow, spleen, and lymph nodes. With the aim to
delineate the cytotoxicity of CAR T cells, we generated anti-CD19
CAR T cells by retroviral transduction of activated mouse CD8+
T cells. These cells efﬁciently recognized Eμ-myc tumor cells
in vitro, leading to their up-regulation of granzyme B and pro-
grammed cell death–1 (PD-1) and the production of IFN-γ. These
hallmarks of activation were not detected in control un-
transduced activated CD8+ T cells or when CAR T cells were
cultured without targets (Fig. S1, A and B). As a mean to detect
tumor cell apoptosis in real time, we expressed a genetically
encoded ﬂuorescence resonance energy transfer (FRET)–based
reporter for caspase-3 activity in Eµ-myc tumor cells (Fig. S1 C).
This reporter is based on the fusion of the CFP and YFP linked by
the caspase-3 target peptide DEVD (Breart et al., 2008; Garrod
et al., 2012). Caspase-3 activity results in the cleavage of the
probe and in loss of FRET. Using ﬂow cytometry, we found that
CAR T cells efﬁciently induced tumor cell apoptosis as measured
by FRET loss in malignant B cells (Fig. S1, D and E), resulting in
the elimination of virtually all tumor cells within a day (Fig. S1
F). Tumor cell apoptosis could also be readily detected using
in vitro time-lapse imaging following contacts with CAR T cells
(Fig. S1 G). These results established a relevant model to study
and visualize CAR T cell cytotoxic activity in vivo.
CAR T cells are trapped in the lung following clustering with
tumor cells
We next thought to study cellular interactions regulating CAR
T cell engraftment/persistence. A previous study that used anti-
CD20 CAR T cells reported that CAR T cells failed to home to the
bone marrow in the presence of endogenous B cells and instead
accumulated in the lungs (James et al., 2009). Using anti-CD19
CAR T cells, we also observed that B cell depletion or the use of
B cell–deﬁcient mice promoted CAR T cell accumulation in the
bone marrow (Fig. 1 A). To gain insight into the underlying
mechanism, we imaged the lungs of recipient mice within
15 min of CAR T cell injection. As shown in Fig. 1 B, numerous
large cellular clusters containing both CAR T and B cells were
detected. This observation suggests that CAR T cells interact
with B cells as they enter the circulation, resulting in the for-
mation of large cellular aggregates that are trapped in the lungs.
We next asked whether, in the context of an established B cell
malignancy, circulating tumors may also favor CAR T cell
trapping in the lungs. This is particularly relevant, as some pa-
tients with B cell lymphoma/leukemia can exhibit high circu-
lating tumor burden. To address this question, RAG2−/− mice
were conditioned with a sublethal dose of irradiation and then
injected or not with Eµ-myc cells. Animals were treated with
CAR T cells once circulating tumors cells became detectable in
blood (typically 10 d later). We found that, rapidly after transfer,
CAR T cells trafﬁcking to the bonemarrowwas largely altered in
tumor bearing mice (Fig. 1 C). The lack of homing to the bone
marrow was associated with the rapid accumulation of cellular
aggregates containing CAR T cells and tumor cells in the lungs
(Fig. 1, D and E). By contrast, these large cellular aggregates were
absent from the lungs of RAG2−/− mice lacking CD19 expressing
cells (Fig. 1, D and E). To conﬁrm that these large cellular ag-
gregates formed in the circulation, we coinjected tumor, CAR,
and control T cells in naive recipients and imaged the lungs
15min later. Cellular clusters comprising CAR T cells and tumors
accumulated in the lung microcirculation already at this early
time point, emphasizing the role of circulating targets (Fig. 1 F).
In these experiments, CAR T cells accumulated in the lungs
twice as much as control CD8+ T cells, indicating that trapping
by circulating tumors was dependent on CAR-mediated inter-
actions. Although it remains possible that this trapping phe-
nomenon is transient, our results indicate that the presence of
B cells limits CAR T cell engraftment in the bone marrow for at
least 3 d (Fig. 1 A). To test the functional consequence of CAR
T cell trapping by circulating targets (B cells and tumors), we
thought to reduce circulating targets using anti-CD20 antibody.
Importantly, our tumor cells expressed very low levels of CD20
(Fig. S2 A) and were not depleted by anti-CD20 treatment in
contrast to B cells (Fig. S2, B–D). By speciﬁcally depleting B cells,
this strategy enabled the removal of a fraction of circulating
targets with minimal direct antitumor effect. The combination
of CAR T cells and anti-CD20 therapy signiﬁcantly reduced the
tumor burden (Fig. S2 D) and was associated with a moderately
prolonged survival (Fig. S2 E). Our results, extending those of a
prior study (James et al., 2009), suggest that circulating targets
(B cells and tumor cells) may represent a substantial hurdle for
CAR T cell therapy by outcompeting bone marrow tumor cells
and/or physically sequestrating CAR T cells in the lung.
CAR T cells exhibit rapid killing dynamics in the bone marrow
We next investigated the extent to which CAR T cells kill ma-
lignant B cells in the bone marrow, a primary site of B cell
lymphoma/leukemia development. Based on our results on CAR
T cell engraftment, CAR T cells were transferred into pre-
conditioned lymphoma-bearing mice when the disease was
largely restricted to the bone marrow with minimal circulating
tumors. Using intravital two-photon imaging, we found that 2 d
after transfer, both CAR T cells and control untransduced acti-
vated CD8+ T cells were detectable in the bone marrow (Fig. 2 A
and Video 1). Notably, the presence of apoptotic tumor cells was
largely restricted to recipients treated with CAR T cells (Fig. 2, A
and B). To characterize CAR T cell killing dynamics and establish
the fraction of tumor cells that was eliminated as a direct con-
sequence of a cellular interaction with CAR T cells, we per-
formed real-time imaging, focusing on tumor cells that
underwent apoptosis (as measured by FRET loss) during the
imaging period. We observed that most tumor apoptotic events
(73%) occurred in the context of a direct cellular contact with a
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Figure 1. Cellular aggregates formed between CAR T cells and circulating tumors accumulate in the lungs. (A) Endogenous B cells limit CAR T cell
accumulation in the bone marrow. RAG2−/− or C57BL/6 mice were injected with a mixture of CAR+ and CAR− GFP+ T cells (containing 60% CAR+ T cells). One
group of mice was treated 3 d before with 50 µg anti-CD20 mAb i.v. The percentage of CAR+ T cells (as detected by hCD34 expression) among GFP+ cells was
assessed in the bone marrow 3 d after T cell transfer using ﬂow cytometry. Red horizontal bars represent mean values. Representative of two independent
experiments (n = 3 mice per group). Unpaired t test was used for statistical analysis. **, P < 0.01; ***, P < 0.001; ns, not signiﬁcant. (B) CAR T cells form clusters
with B cells. Representative two-photon images of the lungs 15 min after CAR T cell injection in CD19-RFP recipients showing the presence of large cellular
aggregates containing CAR T cells (green) and B cells (red). Representative of two independent experiments. Scale bar represents 20 µm. (C) RAG2−/− mice
were conditioned by irradiation (4 Gy) and injected (or not) with Eμ-myc cells. After 2 wk, 10 × 106 CAR T cells and 10 × 106 control T cells were coinjected
i.v., and their trafﬁcking to the bone marrow was assessed 4 h later by ﬂow cytometry. Four mice per group were analyzed in two independent experiments.
Mann–Whitney test was used for statistical analysis. *, P < 0.05. (D and E) CAR T cells form clusters with tumor cells. Mice were conditioned by irradiation (4
Gy) and injected with Eμ-myc-DEVD cells. After 10 d, 10 × 106 CAR T cells were injected i.v. We used untreated RAG2−/− mice as control recipients that did not
contain any CD19+ targets. (D) Representative two-photon images of the lungs showing that CAR T cells form cell aggregates in tumor-bearing mice, but not in
control RAG2−/− recipients. Representative of two independent experiments. (E) Quantiﬁcation of cluster volume in the indicated recipients. The graph shows
the percentage of clusters calculated to be >10,000 µm3. (F) CAR T cells and circulating tumor cells formed clusters that accumulated in the lungs. RAG2−/−
mice were adoptively transferred with a 1:1 mixture of dye-labeled CAR T cells and control untransduced T cells and 5 min later with tumor cells i.v. Two-
photon imaging of the explanted lungs was performed 15 min later. Representative images showing that CAR T cells (red) and tumor cells (blue) in the
circulation formed cellular aggregates detected within minutes in the lungs. Control T cells were not clustered and are shown in orange. Vessels (gray) were
visualized by i.v. injection of a PE-conjugated anti-CD31 mAb. Representative of 12 images in two independent experiments. Scale bar represents 20 µm.
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CAR T cell (Fig. 2, B and C; and Videos 2 and 3). Of note, the
transfer of CAR T cells also increased by 6.5-fold the number of
indirect killing events (Fig. 2 B), in which tumor cells underwent
apoptosis in the absence of any detectable interactions with CAR
T cells (Fig. 2 D and Video 4). While we cannot exclude that CAR
T cells interacted with these tumor cells before we started
imaging, these indirect apoptosis events may reﬂect a boost in
the activity of endogenous effectors and/or an activity of CAR
T cell–derived cytokines.
In most direct killing events, a single CAR T cell could be
detected in interaction with one target cell (Fig. 2 F). For the
majority of direct killing events, we could quantify the time
from target engagement to FRET loss and to target detachment.
Overall, killing was rapid and dynamic as CAR T cells engaged,
killed, and detached from their target in ∼25 min (Fig. 2, G and
H).We cannot exclude that a fraction of CAR T cells may interact
for longer periods during killing due to the constrained duration
of imaging (1–2 h). Thus, despite expressing a high afﬁnity re-
ceptor, anti-CD19 CAR T cells were able to detach rapidly and
quickly resume motility, a property that should favor serial
killing. Consistent with this idea, in a few instances, we ob-
served evidence for killing of adjacent tumors cells by a single
CAR T cell (Fig. 2 E and Video 5). To further conﬁrm the high
killing capacity of CAR T cells, we compared their activity to
Figure 2. Intravital imaging of CAR T cell
dynamics and cytotoxicity in the bone mar-
row in mice with established B cell lym-
phoma. B cell lymphomas were established by
i.v. injection of 0.5 × 106 Eµ-myc-DEVD cells in
C57BL/6 mice after sublethal irradiation (4 Gy).
7 d later, mice were injected i.v. with 20 × 106
puriﬁed CAR T cells or control activated T cells
(untransduced). Bone marrow intravital imag-
ing was performed 40 h after T cell transfer.
(A) Representative two-photon images of
tumor-bearing mice treated with GFP+ control
or CAR T cells. T cells are shown in green, live
tumor cells in gray, and apoptotic tumor cells
in blue. Scale bars represent 50 µm. (B)
Quantiﬁcation of tumor apoptotic events per
hour per mm3 of imaging volume. Events in
which tumors became apoptotic during the
imaging period were recorded. Apoptotic
events were considered as direct killing (n =
55) when a CAR T cell engaged the tumor cells
before the detection of FRET loss. Indirect
events (n = 20) corresponded to tumor cells
undergoing FRET loss without any apparent
interactions with a CAR T cell during the
imaging period. (C and D) Representative
time-lapse images showing examples of tumor
apoptosis. (C) Representative time-lapse im-
ages showing two examples of direct CAR
T cell killing. (D) Time-lapse images illustrating
tumor apoptosis in the absence of apparent
contact with CAR T cells. (E) Example of two
adjacent tumor cells undergoing apoptosis
sequentially upon CAR T cell contact. CAR
T cells (green) are highlighted by red arrow-
heads, and dotted circles show tumor cells
undergoing apoptosis. (F) For direct killing
events, we counted the number of CAR T cells
seen contacting the tumor cell before
apoptosis. For 73% of the direct killing events,
a single CAR T cell was seen interacting with
the tumor cell during the imaging period. (G
and H) Quantiﬁcation of CAR T cell killing dy-
namics. For each direct killing event for which
CAR T cell attachment and detachment was
visualized, we measured time from T cell
contact with tumor cells to killing (G) and T cell
detachment (H). Mean durations are shown by
red horizontal bars. All data shown were rep-
resentative of 10 movies for control T cells and
17 movies for CAR T cells performed in three
independent experiments.
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those of regular CTLs analyzed in the most favorable context
(high-afﬁnity TCR and tumor overexpressing the cognate anti-
gen). Speciﬁcally, we analyzed activated T cells expressing the
high-afﬁnity OT-I TCR against the same tumor transduced to
express high levels of OVA. In vitro and in vivo, CAR T cells
exhibited similar, if not higher anti-tumor activity compared
with OT-I T cells (Fig. S3). Overall, our results demonstrate that
CAR T cell cytotoxic activity plays a major and direct role in
tumor elimination and that rapid killing dynamics in vivo are a
hallmark of CAR T cells.
Functional heterogeneity in CAR T cell–tumor interactions in
the bone marrow
While our imaging experiments revealed that CAR T cell–
mediated tumor killing is a highly rapid event, not all CAR T cell
interactions led to target killing. On average, ∼20% of CAR
T cells were engaged in a killing event during the imaging period
(Fig. 3 A). A fraction of CAR T cells were seen interacting and
detaching from their target without triggering apoptosis (Fig. 3 B
and Video 6). Such heterogeneity in outcomemay originate from
cell–cell variability in cytotoxic potential among CAR T cells
(e.g., variability in cytotoxic granules contents). Alternatively,
differences in CAR T cell signaling upon contact could result in
distinct functional consequences. To test the latter hypothesis,
we focused on Ca2+ signals that are important for both conjugate
formation and the release of cytotoxic granules. CAR T cells
expressing the Twitch2B calcium indicator were imaged in mice
harboring tumors expressing the caspase-3 reporter (Fig. 3 C).
As illustrated in Fig. 3, D and E, and Videos 7 and 8, some CAR
T cells exhibited a strong calcium response upon contact with
tumors cells, while others were poorly responsive despite
forming prolonged contacts. In addition, while killing was as-
sociated with a robust calcium elevation in the CAR T cell, some
interactions led to a detectable calcium response without ap-
parent killing. To test whether the lack of signaling seen in some
CAR T cells was due to a defect in CAR recognition or a more
general block in the calcium pathway, we designed an experi-
ment to stimulate CAR T cells via their endogenous TCR in vivo.
CAR T cells were prepared from OT-I CD8+ T cells and imaged in
the bone marrow of tumor-bearing mice (Fig. 3 F). Injection of
OVA257–264 peptide led to a robust calcium response in all CAR
T cells, suggesting that CAR T cells remained competent for
calcium response (Fig. 3 G). This result supports the idea that
nonresponding CAR T cells exhibit an altered CAR-mediated
signaling that does not originate from a global block in calci-
um mobilization. Altogether, these experiments uncovered an
extensive heterogeneity in signaling during individual CAR
T cell–tumor interactions that impacts killing outcome.
CAR T cell direct activity mediates the rapid clearance of
tumor cells from the bone marrow
The occurence of indirect apoptotic events at the tumor site
raises the question of whether these events play a major role in
tumor regression. When we analyzed the bone marrow on day 5
after CAR therapy, we observed that the vast majority of tumor
cells had been eliminated as detected by intravital imaging and
ﬂow cytometry (Fig. 4, A–D). We also found that the density of
CAR T cells increased by ∼10-fold between day 2 and day 5
(Fig. 4 E). Finally, the percentage of apoptotic tumor cells de-
tected ex vivo by ﬂow cytometry using our reporter system
increased between day 2 and day 5 and was largely correlated
with the percentage of CAR T cells present in the bone marrow
(Fig. 4 F).
To assess whether direct CAR T cell killing is sufﬁcient to
explain the clearance of tumor cells or whether additional re-
cruited effectors play a determinant role, we took advantage of
our experimental measurements of killing dynamics to establish
a mathematical model of tumor outcome. In particular, we cal-
culated the rate of CAR T cell killing (implying a direct contact)
and the observed increase in CAR T cell numbers between day
2 and day 5 from intravital datasets. Tumor growth was de-
scribed with the Gompertz model (Murphy et al., 2016), im-
plying that tumor growth progressively slows down (e.g.,
because of the conﬁned space) but may increase due to cleared
bone marrow niches during CAR T cell–mediated tumor re-
gression. As shown in Fig. 4 G, these simulations supported the
idea that direct CAR T cell activity was sufﬁcient to clear the vast
majority of tumor cells in a few days. Importantly, these results
held true for a wide range of initial tumor growth rate at the
time of CAR T cell transfer (Fig. 4 G). Moreover, the modeling
showed that the observed killing rate per CAR T cell was critical
for tumor regression (Fig. 4 H). In addition, relatively small
differences in early CAR T cell inﬁltration in the bone marrow
substantially impact tumor outcome (Fig. 4 H). This observation
emphasizes the detrimental role that CAR T cell trapping by
circulating targets may have on tumor clearance.
Thus, intravital imaging and mathematical modeling support
the idea that CAR T cells can solely rely on their direct cyto-
toxicity activity rather than on the recruitment and activation of
other effectors to eliminate the bulk of the B cell lymphoma in
the bone marrow within a few days.
Tumor relapse coincides with CAR T cell disappearance
and immunoediting
Recipient mice treated with CAR T cells exhibited a signiﬁcantly
prolonged survival but ultimately relapsed (Fig. 5 A). By day 21
after therapy, the bone marrow was invaded with tumor cells
(Fig. 5 B). At this time, almost no CAR T cells and very few ap-
optotic tumors were detected in the bonemarrow, indicating the
absence of ongoing cytotoxic immune response. CAR T cells
became largely undetectable in the bone marrow and lymph
nodes 4 wk after therapy (Fig. 5 C). Similar to what has been
observed in some patients (Grupp et al., 2013; Maude et al., 2014;
Sotillo et al., 2015; Gardner et al., 2016; Jacoby et al., 2016),
outgrowth of CD19-negative tumors was detected in relapsing
tumors, but interestingly, the emergence of antigen-loss var-
iants occurred in the bone marrow, but not in lymph nodes,
where tumor cells remained CD19-positive (Fig. 5, D and E).
Distinct levels of immunological pressure may therefore exist in
distinct organs, as we have also previously observed in a model
of the graft-versus-leukemia effect (Michonneau et al., 2016). To
test this idea, we compared the ability of CAR T cells to mediate
the killing of transferred CD19+ splenocytes in the lymph nodes
and the bone marrow (Fig. 5 F). As shown in Fig. 5 G, CD19+ cells
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Figure 3. Functional heterogeneity in CAR T cell–tumor interactions in the bonemarrow. (A and B) B cell lymphomas were established by i.v. injection of
0.5 × 106 Eµ-myc-DEVD cells in C57BL/6 mice after sublethal irradiation (4 Gy). 7 d later, mice were injected i.v. with 20 × 106 puriﬁed CAR T cells. Bone
marrow intravital imaging was performed 40 h after T cell transfer. (A) The graph shows the percentage of CAR T cells involved in a direct killing event during
the imaging period. Each dot represents the value calculated in one movie. Data are compiled from three independent experiments. (B) Representative time-
lapse images illustrating that CAR T cell–tumor interactions do not necessarily lead to tumor killing. Scale bar represents 20 µm. Representative of 17 movies
from three independent experiments. (C) Experimental setup. CAR T cell therapy was performed using CAR T cells expressing the Twitch2B genetically
encoded calcium indicator. (D and E) Only a fraction of CAR T cell–tumor interactions trigger calcium signals in the CAR T cell. (D) Representative time-lapse
images showing two CAR T cells (arrowheads) interacting with the same tumor cell (dotted circle) but exhibiting a different calcium response. Calcium el-
evation is reﬂected by an increase of Twitch2B FRET signal. Low and high calcium concentrations are shown in yellow and red, respectively. Tumor cells are
shown in brown. Scale bar represents 20 µm. (E) The tracks and the color-coded calcium response of the two highlighted CAR T cells are shown (upper
images). Some of the contacted tumor cells are highlighted in dotted lines. The bottom graphs show the calcium signals over time during the various contacts
with tumor cells. Tumor killing is highlighted by the red dotted line. Results are representative of three independent experiments (F and G) CAR T cells do not
exhibit a general block in calcium mobilization. Twitch2B-expressing CAR T cells were prepared from CD8+ T cells bearing the OT-I transgenic TCR. During
intravital imaging, OVA257–264 peptide (OVAp) was injected i.v. The calcium responses for two representative CAR T cells are depicted, showing that CAR T cells
that displayed low/no calcium signals during tumor cell contacts exhibited strong calcium responses when stimulated in vivo through their TCR. Representative
of two independent experiments.
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Figure 4. CAR T cells eradicate established B cell lymphoma from the bone marrowwithin 5 d. (A–F) Tumor regression during CAR T cell therapy. B cell
lymphomas were established by i.v. injection of 0.5 × 106 Eµ-myc-DEVD cells in C57BL/6 mice after sublethal irradiation (4 Gy). 7 d later, mice were injected i.v.
with 10–20 × 106 CAR T cells or left untreated. (A) Representative two-photon images of the bonemarrow at days 2 and 5 after CAR T cell transfer showing the
near-complete eradication of the tumor. Live cells appear in gray, apoptotic cells in blue, and CAR T cells in green. Representative of 12 images from two
independent experiments. (B–D) Ex vivo quantiﬁcation of tumor apoptosis in the bone marrow. Flow cytometry analysis was performed at days 2 and 5 after
CAR T cell therapy or in the absence of treatment Representative FACS plots (B) and summary graph (C) showing the percentage of FRET loss in tumor cells. **,
P < 0.01. (D) Absolute numbers of tumors cells recovered from the bone marrow of one tibia at the indicated time points. Means ± SEM are shown. *, P < 0.05;
ns, not signiﬁcant. (E) Bar charts showing CAR T cell density in the bone marrow quantiﬁed by two-photon imaging on days 2 and 5 after CAR T cell transfer.
***, P < 0.001. All data shown in B–E are representative of two independent experiments (n = 3 mice per group). (F) The graph shows the correlation between
the percentage of FRET loss in tumor cells and the percentage of CAR T cells among total CD8+ T cells. Data are compiled from several time points from two
Cazaux et al. Journal of Experimental Medicine 1044
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were efﬁciently depleted from the bone marrow, but not from
lymph nodes, despite CAR T cells being present at a higher
density in lymph nodes (Fig. 5 H). Since we have previously
observed in the context of allogeneic hematopoietic stem cell
transplantation that differential expression of PD-1 ligands could
silence CTL responses in lymph nodes, we assessed PD-L1 ex-
pression in bone marrow and lymph nodes. Consistently, we
found that myeloid cells expressed high levels of PD-L1 in lymph
nodes but not in the bone marrow (Fig. 5 I), suggesting that
differences in tissue microenvironment may contribute to ana-
tomical differences in CAR T cell activity. Our results suggest
that CAR T cell disappearance, emergence of antigen loss
variants and tumor escape in immune-privileged niches may
contribute to tumor relapse after an initial near-complete
elimination phase.
Concluding remarks
By imaging CAR T cell activity at the single-cell level in vivo, we
have established here that the dynamics and outcomes of CAR
T cell interactions are highly diverse and regulated at the
functional and anatomical levels.
Cellular encounters between CAR T cells and circulating
targets resulted in the rapid formation and trapping of CAR
T cell clusters in the lung microcirculation. These results extend
and provide a mechanistic basis for the previously described
accumulation of CAR T cells in the lung in the presence of en-
dogenous B cells (James et al., 2009). Like B cells, we found that
circulating tumor cells strongly prevented CAR T cell trafﬁcking
to the bone marrow, hence representing a substantial hurdle for
CAR T cell engraftment and persistence. These data provide a
likely mechanism for the inverse correlation between CAR T cell
persistence and circulating tumor burden observed in patients
with B cell leukemias (Brentjens et al., 2011). Purging both cir-
culating tumor and normal B cells before CAR T cell transfer
using B cell–targeting treatments (antibodies or chemotherapy)
may offer a clinical beneﬁt by improving CAR T cell engraftment
and persistence.
Our results strongly suggest that the fast killing dynamics of
CAR T cells in vivo contribute to their therapeutic efﬁcacy. Most
killing events occurred after a single CAR T cell contact. Killing
by T cell swarms and multiple contacts, which has been de-
scribed previously in a viral model (Halle et al., 2016), was not
preeminent in the context of CAR T cells. In addition, the rapid
CAR T cell detachment seen after killing contrasts with our
previous observations that conventional CD8+ T cells were se-
questrated by their targets long after killing in a solid tumor
model (Breart et al., 2008). This feature may originate from the
rapid decrease in CAR-mediated signaling associated with the
formation of nonclassical immune synapses observed in a recent
in vitro study (Davenport et al., 2018). Rapid detachment after
target lysis could favor serial tumor cell killing. Although not
preeminent, this mode of killing, which has also been observed
in vitro (Davenport et al., 2015; Liadi et al., 2015), contributed to
the efﬁcacy of CAR T cells in vivo. Notably, not all CAR T cells
were engaged in cytotoxic activity during the imaging periods.
This heterogeneity was reﬂected at the level of signaling, with
some CAR T cells failing to trigger a sustained calcium mobili-
zation upon tumor cell interactions. CAR down-regulation,
downstream signaling defects, or expression of inhibitory
receptors may possibly contribute to this heterogeneity. Despite
the diversity in the outcome of CAR T cell contacts, we provide
experimental and mathematical evidence for a near-complete
tumor elimination within 5 d mediated by direct killing
events. The rapid killing dynamics of at least a fraction of CAR
T cells, together with the progressive accumulation of CAR
T cells in the bonemarrow, were key features that accounted for
tumor clearance. While our study primarily focused on CD8+
CAR T cells, it will be interesting to investigate whether CD4+
CAR T cells exhibit similar killing activity and dynamics.
We show that tumor immunoediting can be site speciﬁc,
highlighting the importance of understanding how antitumor
responses are regulated at the organ level. In particular, our data
suggest anatomical differences in the levels of CAR T cell–
mediated immunological pressure. In particular, CAR T cell ac-
tivity is limited in lymph nodes and is associated with a more
suppressive microenvironment. These ﬁndings, together with
our previous observations in a model of the graft-versus-leu-
kemia effect (Michonneau et al., 2016), suggest that the lymph
nodes may represent a niche for B cell lymphoma to escape
immune surveillance. It is tempting to speculate that such an-
atomical differences in CAR T cell activity may account for the
reduced response rates and delayed efﬁcacy seen in patients
with B cell lymphoma as compared with acute leukemia
(Neelapu et al., 2017; Schuster et al., 2017; Maude et al., 2018;
Park et al., 2018).
In sum, our results establish the large diversity in CAR T cell
contact outcomes in distinct anatomical sites impacting en-
graftment, antitumor activity, and tumor immunoediting. As
illustrated here, deﬁning the relevant immune cell interactions
at the anatomical and microanatomical levels represents an
essential step toward a mechanistic understanding of tumor
immunotherapies and identifying strategies for treatment
optimization.
Materials and methods
Mice and cell lines
6–8-wk-old C57BL/6J mice were purchased from Charles River.
OT-I TCR, Ubi-GFP, Ubi-GFP RAG1−/− OT-I TCR, CD19crexRosa26-
RFP, Eμ-myc, and RAG2−/− mice were bred in our animal facility
independent experiments. Spearman’s correlation coefﬁcient is shown (R2 = 0.98). (G) The tumor evolution in one bone (tibia) was modeled in the presence or
absence of CAR T cells. Simulations were performed considering only the direct CAR T cell cytotoxicity and using different initial tumor growth rates (α = 0.1;
α = 0.5; α = 1.5) corresponding to initial tumor doubling time of 168, 16.8, and 11.2 h respectively (see Materials and methods for details). The graphs suggest
that direct killing events by CAR T cells primarily account for the rapid tumor clearance observed experimentally. (H) Heat map showing the tumor fate at day 5
when considering a range of killing rates and levels of CAR T cell inﬁltration in the bone marrow (modeled for one tibia using α = 0.5). The red square indicates
the values measured experimentally.
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Figure 5. Site-speciﬁc tumor immunoediting following CAR T cell therapy. (A–E) B cell lymphomas were established by i.v. injection of 0.5 × 106 Eµ-myc-
DEVD cells in C57BL/6 mice after sublethal irradiation (4 Gy). 7 d later, mice were injected i.v. with CAR T cells or control activated T cells (untransduced) or left
untreated. (A) CAR T cell therapy prolongs mice survival. Log-rank test was used for statistical analysis. ***, P < 0.001. Data are compiled from three in-
dependent experiments (n = 8 mice in the control group and n = 13 mice in the CAR T cell group). (B) Representative images of the bone marrow on day 21 after
CAR T cell therapy. Images show massive tumor inﬁltration (live tumor cells in gray), a few occasional CAR T cells (green), and rare apoptotic tumors (blue).
Representative of 16 images from two independent experiments. Scale bars represent 20 µm. (C) Disappearance of CAR T cells at late time points. Bar charts
showing the percentage of CAR T cells among CD8+ T cells at the indicated time points in the bone marrow (BM) and in lymph nodes (LN). Data are compiled
from several time points from three independent experiments (n = 3 mice per group). (D and E) Emergence of CD19-negative tumor cells is detected in the
bone marrow but not in lymph nodes. Representative FACS plots (D) and bar charts (E) showing CD19 expression in tumors cells (identiﬁed based on their
ﬂuorescence) in the bone marrow and lymph nodes. Analyses were performed between days 28 and 32. Data are compiled from three independent ex-
periments. FSC, forward scatter. Mann–Whitney test was for statistical analysis. **, P < 0.01. (F–H) CAR T cell exhibit a reduced cytotoxic activity in lymph
nodes. (F) Experimental setup. (G) The in vivo killing of transferred CD19+ splenocytes was compared in the bone marrow and lymph nodes. (H) Frequency of
CAR T cells among total cells as analyzed by ﬂow cytometry. (I) Strong PD-L1 expression in myeloid cells is detected in the lymph nodes, but not the bone
marrow, following CAR T cell therapy. Representative histograms (upper panel) and compiled quantiﬁcation (lower graph). Each dot represents one mouse.
Data are compiled from three independent experiments. Wilcoxon matched-pairs signed rank test was used for statistical analysis. **, P < 0.01; *, P < 0.05.
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under speciﬁc pathogen–free conditions. All animal studies were
approved by the Institut Pasteur Safety Committee in accor-
dance with French and European guidelines (CETEA 2013–0077).
A Burkitt-like lymphoma B cell line was isolated from male Eμ-
myc mice and transduced to express a FRET-based reporter for
caspase-3 activity (Eµ-myc-DEVD line; Michonneau et al., 2016).
Mice were examined every day and sacriﬁced in case of pros-
tration, tousled hair, weakness, ectopic, or nodal tumor mass
>1 cm.
CAR T cell generation, adoptive transfer, and combined in vivo
anti-CD20 therapy
The tCD34.2A.amCD19.CD28IEVζ retroviral vector encoding
anti-CD19 CAR has been described previously (Cheadle et al.,
2014). Brieﬂy, the CAR construct is composed of the anti-
murine CD19 single-chain fragment variable domain derived
from the 1D3 rat hybridoma, the transmembrane and intra-
cellular domains of CD28, and the CD3ζ intracellular domain.
The retroviral vector also encodes the human CD34 molecule
used for identiﬁcation and puriﬁcation of CAR T cells. CD8+
T cells were isolated from lymph nodes of Ubi-GFP OT-I TCR
RAG1−/− or Ubi-GFP mice using a CD8-negative selection kit
(Miltenyi). T cells were activated in plates coated with 2.5 µg
anti-CD3 mAb (clone 17.A2; BioLegend) in the presence of
2.5 µg/ml soluble anti-CD28 mAb (clone 37.51; BioLegend) and
10 ng/ml murine IL-12 (Andrijauskaite et al., 2015; SRP3204;
Sigma-Aldrich). Two rounds of spin-infection were per-
formed at 24 and 48 h after T cell activation using retroviral
particles supplemented with 8 µg/ml polybrene (Merck).
T cells were cultured for 4 additional days in the presence of
25 IU/ml hIL-2 (11147528001; Roche). When indicated, T cells
were also transduced to express the Twitch2B genetically
encoded calcium reporter (Thestrup et al., 2014). Un-
transduced control T cells were activated and cultured in the
same conditions. Puriﬁcation of transduced cells was per-
formed using hCD34 positive selection kit (Miltenyi). Burkitt-
like B cell lymphoma was established in the bone marrow and
lymph nodes by i.v. injection of 0.5 × 106 Eµ-myc cells in
C57BL/6 mice after sublethal irradiation (4 Gy), used as a
conditioning regimen for CAR T cell engraftment (Kochenderfer
et al., 2010). After 7–11 d (when lymphoma cells were detected
in the blood), mice were injected with 10–20 × 106 CAR T cells
or control T cells. In combination therapy experiments, mice
received 50 µg anti-CD20 monoclonal antibody (5D2, mIgG2a;
Genentech) once a week, starting 3 d before CAR T cell
transfer.
Flow cytometry
Cell suspensions were Fc blocked using anti-CD16/32 mAbs
(clone 93; BioLegend) and normal murine serum 1%. Stainings
were performed with the following mAbs: hCD34-BV421 or
Alexa Fluor 647 (561; BioLegend), CD3e-BUV395 (145-2C11; Bio-
Legend) or CD8-BUV395 (53–6.7; BioLegend), PD-1 Pe/Cy7 (J43;
BioLegend), CD19-APC-ﬁre750 (6D5; BioLegend), or PD-L1-PE
(10F.9G2; BioLegend). Intracellular stainings were performed
on CAR or control T cells cultured in the presence or absence
of target cells for 20 h using the Cytoﬁx/Cytoperm kit (BD
Biosciences), Allophycocyanin-conjugated anti-Granzyme B
mAb (GB11; BioLegend) or Alexa Fluor 647–conjugated anti-
IFN-γ mAb (clone XMG1.2; eBioscience). IFN-γ expression
was assayed in the presence of 1 µg/ml Brefeldin A (BD Bio-
sciences). Analyses were performed with a FACSCanto II
cytometer (BD Biosciences) or an LSR/Fortessa (BD Bio-
sciences) and analyzed with FlowJo software version 10.1
(Tree Star). FRET loss was deﬁned as a derived parameter
using the ratio of CFP to FRET ﬂuorescence. FRET loss was
measured on cells ﬁxed with 2% paraformaldehyde solution
(Sigma) immediately after isolation.
Two-photon imaging
Bone marrow intravital imaging was performed 40 h after T cell
transfer by adapting a previously described protocol (Mazo
et al., 1998). Brieﬂy, mice were anesthetized with a mixture of
xylazine (Rompun, 10 mg/kg) and ketamine (Imalgene,
100 mg/kg). The scalp hair was removed, and the scalp was
incised at the midline and then exposed. The jaw was ﬁxed on
the surface of a steel plate to maintain the superior part of the
skull horizontally, and a round 20-mm coverslip was centered
and ﬁxed above the frontoparietal suture after PBS deposition
using a cyanoacrylate-based glue. During imaging, mice were
supplied with oxygen, and their temperature was maintained at
37°C with a heating pad. Two-photon imaging was performed
with an upright microscope FVMPE-RS (OLYMPUS) and a 25×/
1.05 NA water-dipping objective (OLYMPUS). Excitation was
provided by an Insight deep see dual laser (Spectra Physics)
tuned at 880 nm. CFP and FRET were detected using 483/32 and
542/27 ﬁlters, respectively. To create time-lapse sequences, we
typically scanned a 30-µm-thick volume of tissue at 5-µm
Z-steps and 60-s intervals. Videos were processed and ana-
lyzed with Imaris software (Bitplane) or Fiji software (1.49 m;
ImageJ). Videos and ﬁgures based on two-photonmicroscopy are
shown as two-dimensional maximum intensity projections of
three-dimensional data. Analysis of contact duration during
killing was restricted to events in which initial encounter could
be imaged. Pulmonary lobes were imaged ex vivo on a Petri dish
topped by a round 20-mm coverslip.
Mathematical modeling of tumor dynamics during CAR
T cell therapy
Wemodeled the growth of tumors and their destruction by CAR
T cells by considering cells and their interactions within the
bone marrow compartment of a single bone (based on a com-
bination of imaging and ﬂow cytometry measurements made on
tibias).
Tumor growth was described with the Gompertz model,
which is a classical ordinary differential equation model in
which the tumor growth rate slows down exponentially over
time. This implies that the tumor growth rate is higher for small
tumors than for large tumors, thus also taking into account a
potential increase of tumor proliferation during CAR T cell
therapy due to cleared bone marrow niches. Similar to Murphy
et al. (2016), we reparameterized the Gompertz model in terms
of initial cell numbers and included a term to describe killing by
CAR T cells:
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dB
dt
 B α − βln B
B0
  
− kC,
where B represents the number of tumor B cells, B0 is the
number of tumor cells at day 0 (time of CAR T cell transfer), α
represents the initial growth rate of the tumor, β describes the
rate at which tumor growth slows, C represents the number of
CAR T cells, and k represents the killing rate per CAR T cell.
In the absence of CAR T cells, no killing occurs and an ana-
lytical solution to this model (Benzekry et al., 2014) is
B(t)  B0e
α
β 1−e−βt( ).
Based on measurements of absolute tumor cell numbers on days
2 and 5 (Fig. 4 D; the latter exhibiting a 17% increase in tumor
size compared with the former, corresponding to a growth rate
of 0.054 d−1) in the absence of CAR T cell treatment, we set
boundary conditions for B2 and for B5B2. For each initial growth
rate α, the analytical solution can be solved simultaneously with
these boundary conditions to determine unique values for B0
and β.
To determine the killing rate around day 2 based on our in-
vivo imaging data, we divided the observed number of apoptotic
events due to direct killing by the number of CAR T cells ob-
served in the movie (13 movies were analyzed). The average of
these killing rates per video was equal to 0.2 kills CAR−1 h−1,
which we used as a default value for k. Killing of targets by
T cells is expected to saturate with increasing cell densities,
which can be described with a general saturation function
(Gadhamsetty et al., 2014). However, early after CAR infusion,
individual T cells encounter a surplus of tumor cells and are
therefore expected to kill at their maximum rate. The general
saturation function in that case reduces to the killing term we
applied here (Gadhamsetty et al., 2014; i.e., −kC). At later stages
the killing rate per CAR T cell may decrease, but this would
occur only at a stage where the tumor is already controlled by
CAR T cells and does not affect the overall conclusions with
respect to tumor control.
We included the increase in CAR T cell numbers into the
simulations with the ordinary differential equation model,
which was based on the data shown in Fig. 4 E. Speciﬁcally, the
increase in average number of intratumoral CAR T cells over
time was considered to be linear according to the following
relation:
C(t)  max C5 − C2
3
t + C2 − 2(C5 − C2)3 ,0
 
,
where C2 and C5 are the average observed numbers of CAR
T cells at day 2 (40 h) and day 5 (112 h), respectively. The term
C5−C2
3 corresponds to the daily increase in CAR T cells (assumed to
be linear).
Simulations were run for different initial tumor growth rates
in order to investigate the sensitivity of the results to that un-
known parameter. Moreover, the killing rate and the inﬁltration
rate of CAR T cells were varied in order to investigate the im-
portance of these parameters in regression of the tumor. The
model parameters inferred from the three tested initial growth
rates (see Fig. 4 G) were: [α = 0.1, β = 0.19, B0 = 898000]; [α =0.5,
β = 0.695, B0 = 618000]; [α =1.5, β = 1.07, B0 = 309000]. All
simulations were run in R (version 3.3.2) using the package
deSolve (version 1.14).
Statistical analysis
All statistical tests were performed with Prism v.6.0b (Graph-
Pad). t, Mann–Whitney, or Kruskal–Wallis tests were used as
indicated, and Dunn’s test was used for multiple comparisons
correction. Data are expressed as mean ± SEM.
Online supplemental material
Fig. S1 shows the detection of CAR T cells mediated tumor killing
in vitro using a genetically encoded apoptosis reporter. Fig. S2
shows that removal of circulating B cells increases CAR T cell
activity. Fig. S3 compares CAR T cell and OT-I T cell killing
in vitro and in vivo. Video 1 shows intravital bone marrow
imaging of lymphoma-bearing mice treated with control T cells.
Videos 2 and 3 illustrate efﬁcient and rapid killing of B cell tu-
mors by CAR T cells in the bone marrow. Video 4 highlights an
example of a B cell tumor undergoing apoptosis without ap-
parent CAR T cell contacts. Video 5 shows CAR T cell serial
killing of adjacent tumor cells in the bone marrow. Video 6
shows an example of a CAR T cell forming prolonged interac-
tions with tumor cells without inducing their apoptosis. Video 7
highlights a CAR T cell with high calcium responses upon in-
teractions with tumor cells. Video 8 shows an example of CAR
T cell with weak calcium responses upon interactions with
tumor cells.
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